USOR 2409824098 - Ph3 study of FOLFIRI in participants with metastatic colorectal cancer

A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy

Disease Types: Colorectal

Available at: Arlington Heights, Chicago, Niles